Power J, Cross R L, Harris D A
Biochim Biophys Acta. 1983 Jul 29;724(1):128-41. doi: 10.1016/0005-2728(83)90034-8.
The ox heart mitochondrial inhibitor protein may be iodinated with up to 0.8 mol 125I per mol inhibitor with no loss of inhibitory activity, with no change in binding affinity to submitochondrial particles, and without alteration in the response of membrane-bound inhibitor to energisation. Tryptic peptide maps reveal a single labelled peptide, consistent with modification of the single tyrosine residue of the protein. A single type of high-affinity binding site (Kd=96 . 10 (-9)M) for the inhibitor protein has been measured in submitochondrial particles. The concentration of this site is proportional to the amount of membrane-bound F1, and there appears to be one such site per F1 molecule. The ATp hydrolytic activity of submitochondrial particles is inversely proportional to the occupancy of the high-affinity binding site for the inhibitor protein. No evidence is found for a non-inhibitory binding site on the membrane or on other mitochondrial proteins. In intact mitochondria from bovine heart, the inhibitor protein is present in an approx. 1:1 ratio with F1. Submitochondrial particles prepared by sonication of these mitochondria with MgATP contain about 0.75 mol inhibitor protein per mol F1, and show about 25% of the ATPase activity of inhibitor-free submitochondrial particles. Additional inhibitor protein can be bound to these particles to a level of 0.2 mol/mol F1, with consequent loss of ATPase activity. If MgATP is omitted from the medium, or inhibitors of ATP hydrolysis are present, the rate of combination between F1 and its inhibitor protein is very much reduced. The equilibrium level of binding is, however, unaltered. These results suggest the presence of a single, high-affinity, inhibitory binding site for inhibitor protein on membrane-bound F1. The energisation of coupled submitochondrial particles by succinate oxidation or by ATP hydrolysis results in both the dissociation of inhibitor protein into solution, and the activation of ATP hydrolysis. At least 80% of the membrane-bound F1-inhibitor complex responds to this energisation by participating in a new equilibrium between bound and free inhibitor protein. This finding suggests that a delocalised energy pool is important in promoting inhibitor protein release from F1. Dissipation of the electrochemical gradient by uncouplers, or the binding of oligomycin or efrapetin effectively blocks energised release of the inhibitor protein. Conversely, the addition of aurovertin or adenosine 5'--[beta, lambda--imido]triphosphate enhances energy-driven release. The mode of action of various inhibitors on binding and energised release of the protein inhibitor is discussed.
牛心线粒体抑制蛋白可被碘化,每摩尔抑制剂最多结合0.8摩尔的¹²⁵I,而抑制活性无损失,与亚线粒体颗粒的结合亲和力无变化,且膜结合抑制剂对能量化的反应也无改变。胰蛋白酶肽图谱显示有一个单一的标记肽,这与该蛋白单个酪氨酸残基的修饰一致。在亚线粒体颗粒中已测得抑制剂蛋白有单一类型的高亲和力结合位点(Kd = 96×10⁻⁹M)。该位点的浓度与膜结合F1的量成正比,且每个F1分子似乎有一个这样的位点。亚线粒体颗粒的ATP水解活性与抑制剂蛋白高亲和力结合位点的占有率成反比。未发现膜或其他线粒体蛋白上存在非抑制性结合位点的证据。在牛心的完整线粒体中,抑制剂蛋白与F1的比例约为1:¹。用MgATP超声处理这些线粒体所制备的亚线粒体颗粒,每摩尔F1含有约0.75摩尔抑制剂蛋白,其ATP酶活性约为无抑制剂亚线粒体颗粒的25%。额外的抑制剂蛋白可与这些颗粒结合至0.2摩尔/摩尔F1的水平,从而导致ATP酶活性丧失。如果培养基中省略MgATP或存在ATP水解抑制剂,F1与其抑制剂蛋白之间的结合速率会大大降低。然而,结合的平衡水平未改变。这些结果表明膜结合F1上存在一个单一的、高亲和力的、抑制剂蛋白的抑制性结合位点。琥珀酸氧化或ATP水解使偶联的亚线粒体颗粒能量化,会导致抑制剂蛋白解离进入溶液,并激活ATP水解。至少80%的膜结合F1 - 抑制剂复合物通过参与结合态和游离抑制剂蛋白之间的新平衡来响应这种能量化。这一发现表明,一个离域的能量池在促进抑制剂蛋白从F1释放中很重要。解偶联剂使电化学梯度消散,或寡霉素或埃拉菌素的结合有效地阻断了抑制剂蛋白的能量化释放。相反,添加金雀花碱或腺苷5'-[β,λ-亚氨基]三磷酸可增强能量驱动的释放。讨论了各种抑制剂对蛋白抑制剂结合和能量化释放的作用方式。